GPR161 and central nervous system neoplasm: The latest edition of the WHO CNS tumor classification divides MBSHH into TP53 mutated and wild type, respectively.30,31 We assessed TP53 mutation status across all MBSHH and observed that all GPR161-associated MBSHH were TP53 wild type and represented 4.1% (six of 147) of pediatric patients with MBSHH,TP53-wt.